#ASH18: Re­gen­eron's bis­pe­cif­ic REGN1979 of­fers eye-catch­ing 80% CR rate in fol­lic­u­lar lym­phoma, spurring swift shift to piv­otal study

As one of the world’s top — and cer­tain­ly best paid — an­ti­body drug de­vel­op­ers, Re­gen­eron’s George Yan­copou­los tends to at­tract a con­sid­er­able amount of at­ten­tion when he gets ex­cit­ed by one of his clin­i­cal projects. And to­day you’ll find him ea­ger­ly tout­ing a bis­pe­cif­ic ther­a­py that the R&D chief has sky-high hopes for.

Ev­i­dent­ly with good rea­son.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER